| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2014-02-28 | Abingworth (UK) | £225 million (€ 269.8 million) | Fundraising | |||
| 2014-02-27 | Santhera Pharmaceuticals (Switzerland) | CHF 1 Million (€ 0.8 million) | private placement | IGLU Group (Switzerland) | Neuromuscular diseases - Rare diseases | Private placement |
| 2014-02-27 | Horizon Discovery (UK) | £25 million (€30.4 million) | IPO | IPO | ||
| 2014-02-24 | BioInvent (Sweden) | MSEK 64 (€ 7.16 million) | Cancer - Oncology | Private placement | ||
| 2014-02-19 | Covagen (Switzerland) | CHF 44.9 million (€36.7 million) | series B financing round | Gimv (Belgium), Ascent Biomedical Ventures (USA), Edmond de Rothschild Investment Partners (France), MP Healthcare Venture Management (USA), Novartis Venture Fund (Switzerland), Seroba Kernel Life Sciences (Ireland), Ventech (France), Baxter Ventures (USA) | Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Cancer - Oncology | Series B financing round |
| 2014-02-18 | Novimmune (Switzerland) | CHF 60 million ($66 million - €49.1 million) | series B financing round | Rosetta Capital Limited (UK) | Cancer - Oncology | Series B financing round |
| 2014-02-18 | SynAffix (The Netherlands) | undisclosed | series A financing round | Aravis (Switzerland), BioGeneration Ventures (the Netherlands), MS Ventures (Germany), BOM Capital (the Netherlands) | Cancer - Oncology | Series A financing round |
| 2014-02-17 | Advanced Accelerator Applications (France) | €41 million | capital increase | Tamburi Investment Partners Group (Italy), HBM Healthcare Investments (Switzerland) | Diagnostic - Cancer - Oncology | Capital increase |
| 2014-02-12 | Rhenovia (France) | € 540,000 | series B financing round | historical shareholders | CNS diseases | Series B financing round |
| 2014-02-10 | Audion Therapeutics (The Netherlands) | undisclosed | Series A financing round | Eli Lilly (USA) | Otorhinolaryngology | Series A financing round |
| 2014-02-10 | Melinta Therapeutics (USA - CT) | $70 million | series C financing round | Vatera Healthcare Partners (USA - NY) Santo Domingo Group undisclosed new and existing investors | Infectious diseases | Series C financing round |
| 2014-02-09 | Atara Biotherapeutics (USA - CA) | private placement | Cancer - Oncology - Kidney diseases - Renal diseases | Private placement | ||
| 2014-02-06 | Mologen (Germany) | €15.7 million | private placement | Cancer - Oncology | Private placement | |
| 2014-02-05 | BerGenBio (Norway) | NOK75 million (€ 10 million) | private placement | Cancer - Oncology | Private placement | |
| 2014-02-05 | Anergis (Switzerland) | CHF 8 million (€6.5 million) | financing round | Sunstone Capital (Denmark), BioMedInvest (Switzerland), Renaissance PME/Vinci Capital (Switzerland) | Allergic diseases - Immunological diseases | Financing round |
| 2014-02-05 | SARTRIC consortium (BioVersys [Switzerland] SARomics Biostructures [Sweden] | grant | European Eurostars Programme (EU) | Grant | ||
| 2014-02-03 | Galapagos (Belgium) | €2.3 million | grant | Flemish Agency for Innovation by Science and Technology (IWT) (Belgium) | Grant | |
| 2014-01-30 | Nightstar (UK) | £12 million | seed financing round | Syncona (UK) | Ophtalmological diseases | Financing round |
| 2014-01-23 | Genmab (Denmark) | DKK 998 million (€ 133.7 million) | private placement | selected institutional investors | Cancer - Oncology | Private placement |
| 2014-01-21 | Synthelis (France) | € 610,000 | Alpes Developpement Durable Investissement (A2D-Invest) (France), Grenoble Angels (France), Rhone-Alpes Creation (France), Savoie Angels (France), SudRhoneAlpes Capital (France), Viaduc Participations (France) | Financing round |
